金涌，教授，硕士生导师
1969年10月生，安徽医科大学药学院院长。安徽医科大学教学名师。中国药学会和药理学会会员，安徽省药理学会理事，安徽省药学会药物分析专业委员会和临床试验专业委员会副主任委员，药剂学和临床药理专业委员会常务委员，《安徽医药》编委。
长期从事生物药剂学和体内药物分析学研究，主要研究领域为芳香烃受体与肝脏疾病。作为主要参加者参与多项国家自然科学基金、国家重大基础研究前期（973前期）研究专项、国家科技部863立项项目等研究。
主持省部级科研项目多项，近年来发表学术论文50余篇，其中SCI收录30余篇，先后获安徽省自然科学二、三等奖各一项。安徽省教学成果特等奖和一等奖各一项。

主要代表作：
Xia H, Zhu X, Zhang X, Jiang H, Li B, Wang Z, Li D,Jin Y. Alpha-naphthoflavone attenuates non-alcoholic fatty liver disease in oleic acid-treated HepG2 hepatocytes and in high fat diet-fed mice.Biomed Pharmacother. 2019 Oct; 118: 109287.
Zhu XY, Xia HG, Wang ZH, Li B, Jiang HY, Li DL, Jin R,Jin Y. In vitro and in vivo approaches for identifying the role of aryl hydrocarbon receptor in the development of nonalcoholic fatty liver disease.Toxicol Lett. 2020 Feb 1; 319: 85-94.
Cao Y, Gao H, Xia H, Zhu X, Li B, Zhou X,Jin Y. Development and Evaluation of a Water-in-oil Microemulsion Formulation for the Transdermal Drug Delivery of Teriflunomide (A771726).Chem Pharm Bull (Tokyo). 2019; 67(8): 786-794.
Xu M, Yu Q, Zhao Q, Chen W, Lin Y,Jin Y. Development and in vitro-in vivo evaluation of a water-in-oil microemulsion formulation for the oral delivery of troxerutin.Drug Dev Ind Pharm. 2016;42(2):280-7.
Gao H, Cao Y, Xia H, Zhu X,Jin Y. CYP4A11 is involved in the development of nonalcoholic fatty liver disease via ROSinduced lipid peroxidation and inflammation.Int J Mol Med. 2020 Apr;45(4):1121-1129.
Chen W, Lin YJ, Zhou XY, Chen H,Jin Y. Rosiglitazone protects rat liver against acute liver injury associated with the NF-κB signaling pathway.Can J Physiol Pharmacol. 2016 Jan;94(1):28-34.